Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Drug Res (Stuttg) ; 69(2): 83-92, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29996172

ABSTRACT

There is a growing global interest in hypertension due to its associated complications including renal dysfunction in patients. The thyroid system reportedly regulates renal function in both animal and human. The present study investigated the therapeutic efficacy of taurine on renal and thyroid dysfunctions in hypertensive rats. Hypertension was induced by oral administration of nitric oxide synthase inhibitor, N-nitro L-arginine-methyl-ester (L-NAME), at 40 mg/kg body weight to the male Wistar rats for 14 consecutive days. The hypertensive rats were subsequently treated with either taurine (100 and 200 mg/kg) or reference drug atenolol (10 mg/kg) for another 14 consecutive days. Hypertensive rats showed renal damage evidenced by elevated plasma creatinine and urea levels when compared with normotensive control rats. Furthermore, L-NAME-induced hypertensive rats showed decreased circulatory concentrations of thyroid stimulating hormone, thyroxine, triiodothyronine and the ratio of triiodothyronine to thyroxine. The marked decrease in the renal antioxidant enzyme activities and nitric oxide level was accompanied by significant increase in myeloperoxidase activity and biomarkers of oxidative stress in hypertensive rats. Histological examination of kidneys from hypertensive rats revealed congestion of blood vessels, hemorrhagic lesion and disorganized glomerular structure. However, treatment with taurine or atenolol significantly reversed the suppression of thyroid function, ameliorated renal oxidative stress and histopathological lesions in L-NAME-induced hypertensive rats. Taurine may be a useful chemotherapeutic supplement in enhancing renal and thyroid functions in hypertensive patients.


Subject(s)
Hypertension/complications , Renal Insufficiency/prevention & control , Taurine/administration & dosage , Thyroid Gland/physiopathology , Animals , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Atenolol/pharmacology , Atenolol/therapeutic use , Blood Pressure/drug effects , Dietary Supplements , Disease Models, Animal , Humans , Hypertension/chemically induced , Hypertension/drug therapy , Kidney/drug effects , Kidney/pathology , Male , NG-Nitroarginine Methyl Ester/toxicity , Oxidative Stress/drug effects , Rats , Rats, Wistar , Renal Insufficiency/etiology , Renal Insufficiency/pathology , Thyroid Gland/drug effects
2.
J Diet Suppl ; 15(3): 269-284, 2018 May 04.
Article in English | MEDLINE | ID: mdl-28800275

ABSTRACT

Parquetina nigrescens is commonly used to treat diseases in humans and animals in developing countries, including Nigeria. This study evaluates the effects of its polyphenol-rich fraction (prf) on dichlorvos-induced cardio- and renal toxicity. There were several factors assessed during this study, including cardiac and renal markers, serum myeloperoxidase and xanthine oxidase, and electrocardiograph (ECG) changes. The changes in electrocardiograph (ECG) were recorded. Immunohistochemistry of cardiac and renal p38 and nitrotyrosine was determined. Dichlorvos exposure caused a significant decrease in L-glutathione (reduced glutathione) and other antioxidant enzymes with increases in malondialdehyde, myeloperoxidase, advanced oxidation protein products, and protein carbonyl levels. It also brought about alterations in microanatomy of the heart and kidneys accompanied by increases in serum creatinine and urea levels. Exposure to dichlorvos induced prolonged QRS interval and shortened QT durations in rats. Immunohistochemistry revealed lower expressions of cardiac nitrotyrosine and renal p38 (mitogen-activated protein kinase; MAPK) in rats treated with prf of P. nigrescens. Combining all, prf of P. nigrescens demonstrated antioxidant as well as protective properties in the heart and kidneys of rats exposed to dichlorvos. It ameliorated dichlorvos-induced cardio- and nephrotoxicity giving credence to its use in ethnomedicine.


Subject(s)
Cryptolepis/chemistry , Dietary Supplements , Organophosphate Poisoning/prevention & control , Plant Components, Aerial/chemistry , Plant Extracts/therapeutic use , Polyphenols/therapeutic use , Protective Agents/therapeutic use , Administration, Oral , Animals , Biomarkers/blood , Biomarkers/metabolism , Cryptolepis/growth & development , Dichlorvos/administration & dosage , Dichlorvos/antagonists & inhibitors , Dichlorvos/toxicity , Dietary Supplements/analysis , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Insecticides/administration & dosage , Insecticides/antagonists & inhibitors , Insecticides/toxicity , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Kidney/physiopathology , Male , Nigeria , Organophosphate Poisoning/metabolism , Organophosphate Poisoning/pathology , Organophosphate Poisoning/physiopathology , Plant Components, Aerial/growth & development , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Polyphenols/administration & dosage , Polyphenols/analysis , Polyphenols/isolation & purification , Protective Agents/administration & dosage , Protective Agents/chemistry , Protective Agents/isolation & purification , Random Allocation , Rats, Wistar , Renal Insufficiency/etiology , Renal Insufficiency/prevention & control , Tyrosine/agonists , Tyrosine/analogs & derivatives , Tyrosine/antagonists & inhibitors , Tyrosine/metabolism , Ventricular Dysfunction/etiology , Ventricular Dysfunction/prevention & control , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/chemistry , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Biomed Pharmacother ; 97: 181-189, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29091864

ABSTRACT

The beneficial health effects of taurine on hypertension have been demonstrated previously in both experimental and epidemiological studies. However, the role of taurine in reproductive dysfunction associated with hypertension has not been investigated. The present study evaluated the therapeutic efficacy of taurine on reproductive deficits in N-nitro-l-arginine methyl ester (L-NAME)-induced hypertensive rats. Sixty male Wistar rats were randomly assigned into six groups namely control, taurine alone, L-NAME alone (40mg/kg) or L-NAME treated with either taurine (100 and 200mg/kg) or reference drug atenolol (10mg/kg) for 28 consecutive days. Results indicated that taurine treatment significantly abrogated L-NAME-induced increase in systolic, diastolic and mean arterial pressures when compared with hypertensive control. Administration of taurine markedly increased antioxidant enzymes activities and glutathione level whereas it suppressed the increase in biomarkers of oxidative stress in the testes and epididymis of L-NAME-induced hypertensive rats. Moreover, taurine significantly reversed hypertension mediated decreases in circulatory concentrations of luteinizing hormone, follicle-stimulating hormone and testosterone whereas it increased testicular sperm number, epididymal sperm number and sperm progressive motility in the hypertensive rats. Furthermore, taurine abrogated the suppression of marker enzymes of testicular function namely acid phosphatase, alkaline phosphatase and lactate dehydrogenase and preserved the histo-architectures of the testes and epididymis in L-NAME-induced hypertensive rats. Taken together, the findings from this study highlight the beneficial role of taurine in reproductive system of L-NAME-induced male hypertensive rats. Taurine supplementation may be a good clinical approach to prevent reproductive deficits in male hypertensive patients.


Subject(s)
Antioxidants/pharmacology , Epididymis/metabolism , Hypertension/metabolism , Spermatogenesis/physiology , Taurine/pharmacology , Testis/metabolism , Animals , Epididymis/drug effects , Hypertension/chemically induced , Male , NG-Nitroarginine Methyl Ester/toxicity , Rats , Rats, Wistar , Spermatogenesis/drug effects , Taurine/therapeutic use , Testis/drug effects
4.
J Basic Clin Physiol Pharmacol ; 29(1): 19-27, 2018 Jan 26.
Article in English | MEDLINE | ID: mdl-29016351

ABSTRACT

BACKGROUND: The use of doxorubicin (DOX) as an antineoplastic agent has been greatly limited because of the myriad of toxic sequelae associated with it. The aim of this study was to assess the protective effects of gallic acid (GA) on DOX-induced cardiac toxicity in rats. METHODS: Sixty male rats (Wistar strain) were used in this study. They were divided into six groups (A-F) each containing 10 animals. Group A was the control. Rats in Groups B, C, and D were treated with DOX at the dosage of 15 mg/kg body weight i.p. Prior to this treatment, rats in Groups C and D had been treated orally with GA for 7 days at the dosage of 60 and 120 mg/kg, respectively. Animals from Groups E and F received only 60 and 120 mg/kg GA, respectively, which were administered orally for 7 days. RESULTS: The exposure of rats to DOX led to a significant (p<0.05) decrease in the cardiac antioxidant defence system and elevation of creatine kinase myocardial band and lactate dehydrogenase. The electrocardiography results showed a significant decrease in heart rate, QRS, and QT-segment prolongation. GA alone improved the antioxidant defence system. CONCLUSIONS: The GA pretreatment significantly alleviated GA-associated ECG abnormalities, restored the antioxidant status and prevented cardiac damage.


Subject(s)
Cardiotoxicity/drug therapy , Doxorubicin/adverse effects , Gallic Acid/pharmacology , Heart/drug effects , Animals , Antioxidants/metabolism , Cardiotoxicity/metabolism , Creatine Kinase/metabolism , Electrocardiography/methods , Heart Rate/drug effects , L-Lactate Dehydrogenase/metabolism , Male , Myocardium/metabolism , Protective Agents/pharmacology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...